1. Home
  2. TULP vs GTBP Comparison

TULP vs GTBP Comparison

Compare TULP & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bloomia Holdings Inc. Common Stock

TULP

Bloomia Holdings Inc. Common Stock

SELL

Current Price

$2.31

Market Cap

12.0M

ML Signal

SELL

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$3.03

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TULP
GTBP
Founded
1990
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
12.4M
IPO Year
2026
2016

Fundamental Metrics

Financial Performance
Metric
TULP
GTBP
Price
$2.31
$3.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.4K
★ 72.3K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $18,800,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$0.22
52 Week High
$4.99
$236.00

Technical Indicators

Market Signals
Indicator
TULP
GTBP
Relative Strength Index (RSI) 42.34 26.91
Support Level $2.00 $0.22
Resistance Level $2.50 $7.50
Average True Range (ATR) 0.14 0.45
MACD 0.05 0.07
Stochastic Oscillator 53.09 0.00

Price Performance

Historical Comparison
TULP
GTBP

About TULP Bloomia Holdings Inc. Common Stock

Bloomia Holdings Inc is a specialty agricultural company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: